top of page
Laxxon's Oral GLP-1 Agonist Treatment, LXM.2, Granted Funding by ESF Plus and the Free State of Thuringia
Laxxon has received a grant by Freistaat Thüringen and the ESF Plus (European Social Fund) for the further development of LXM.2.
Laxxon Medical
Mar 114 min read
bottom of page